Purpose
We aimed to determine the demographic and epidemiologic variables that are associated with no treatment in lung cancer patients.
Materials and Methods
Patient data were collected from the Korean National Health Insurance Database. The lung cancer group included patients with an initial diagnosis of lung cancer between January 2009 and December 2014. Treated cases were defined as those that underwent surgery, radiation, or chemotherapy until death, after the diagnosis of lung cancer. Risk of no treatment was calculated by multiple logistic regression analysis.
Results
Among the 2148 new cases of lung cancer from 2009 to 2104, 612 (28.4%) were not treated. Risk of no treatment was higher in the following patients: patients in their 60s (odds ratio [OR], 1.18; 95% confidence interval [CI], 0.75 to 1.84), 70s (OR, 3.64; 95% CI, 2.41 to 5.50), and >80 years old (OR, 16.55; 95% CI, 10.53 to 25.03) than those in their 50s; patients with previous myocardial infarction (OR, 2.07; 95% CI, 1.01 to 4.25) or chronic kidney disease (OR, 2.88; 95% CI, 1.57 to 5.30); and patients diagnosed at a non-referral hospital (OR, 1.40; 95% CI, 1.01 to 1.92) or primary care provider (OR, 1.81; 95% CI, 1.43 to 2.29) compared with referral hospital. Low-income patients receiving Medicaid were 1.75 times (95% CI, 1.14 to 2.68) more likely to forgo treatment than high-income patients (upper 20%). Risk was not associated with sex or the year in which the lung cancer was diagnosed.
Conclusion
Age predominantly determines whether patients with lung cancer undergo anti-cancer treatment.
Citations
Citations to this article as recorded by
Efficacy of preoperative pulmonary rehabilitation in lung cancer patients: a systematic review and meta-analysis of randomized controlled trials Yalun Guo, Mengdie Pan, Meidi Xiong, Miao Liu, Na Zhu, Haoxu Dong, Chunhua Zhang Discover Oncology.2025;[Epub] CrossRef
Clinical efficacy and safety of sintilimab plus oral vinorelbine as first-line treatment for newly diagnosed stage IIIB–IV nonsmall cell lung cancer patients with performance status 2 or age ≥75 years Wenzhong Su, Jianqiang Li Anti-Cancer Drugs.2025; 36(5): 401. CrossRef
Age differences in the treatment of lung cancer–a cohort study among 42,000 patients from Germany Nikolaj Rischke, Josephine Kanbach, Ulrike Haug Journal of Cancer Research and Clinical Oncology.2024;[Epub] CrossRef
Giant Ovarian Cyst Presenting as an Intra-Abdominal Mass Dhruv Narayan, Archit Jain, Amit Shrivastava, Gunjan Jindal, Komal Yadav Journal of Evolution of Medical and Dental Sciences.2022; 11(3): 428. CrossRef
Development and Validation of a Prognostic Nomogram in Lung Cancer With Obstructive Sleep Apnea Syndrome Wei Liu, Ling Zhou, Dong Zhao, Xiaofeng Wu, Fang Yue, Haizhen Yang, Meng Jin, Mengqing Xiong, Ke Hu Frontiers in Medicine.2022;[Epub] CrossRef
Prognostic outcome of treatment modalities for epidermal growth factor receptor-mutated advanced lung cancer Seung Hun Jang, Dong Yoon Lee, Jihyeon Jeong, Won-Il Choi The Korean Journal of Internal Medicine.2022; 37(4): 811. CrossRef
Effects of Nurse Navigators During the Transition from Cancer Screening to the First Treatment Phase: A Systematic Review and Meta-analysis Jiwon Oh, Sukhee Ahn Asian Nursing Research.2021; 15(5): 291. CrossRef
Small cell lung cancer starting with diabetes mellitus: Two case reports and literature review Tong Zhou, Yao Wang, Xue Zhao, Yang Liu, Ying-Xuan Wang, Xiao-Kun Gang, Gui-Xia Wang World Journal of Clinical Cases.2019; 7(10): 1213. CrossRef
Trends in life expectancy among medical aid beneficiaries and National Health Insurance beneficiaries in Korea between 2004 and 2017 Jinwook Bahk, Hee-Yeon Kang, Young-Ho Khang BMC Public Health.2019;[Epub] CrossRef